Medically reviewed on Nov 15, 2018
(FER ik SIT rate)
- Tetraferric Tricitrate Decahydrate
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Auryxia: Ferric iron 210 mg (ferric citrate 1 g) [contains fd&c blue #2 aluminum lake, fd&c red #40 aluminum lake, fd&c yellow #6 aluminum lake]
Brand Names: U.S.
- Iron Salt
- Phosphate Binder
Hyperphosphatemia: Lowers serum phosphate by binding to dietary phosphate in the GI tract; product precipitates as insoluble ferric phosphate and is excreted in feces.
Iron deficiency anemia: Oxidized ferric iron circulates bound to transferrin where it is incorporated into hemoglobin after it is transported through enterocytes into the blood.
Use: Labeled Indications
Hyperphosphatemia: For the control of serum phosphorus levels in patients with chronic kidney disease (CKD) receiving dialysis
Iron deficiency anemia: Treatment of iron deficiency anemia in patients with CKD not on dialysis
Iron overload syndromes (eg, hemochromatosis)
Note: Each tablet contains 210 mg of ferric iron equivalent to 1 g ferric citrate.
Initial: Two tablets (420 mg ferric iron) 3 times daily
Maintenance: Increase or decrease dose by 1 tablet or 2 tablets (ferric iron 210 mg to 420 mg) as needed at 1-week or longer intervals to achieve target serum phosphorus levels (maximum dose: 12 tablets [ferric iron 2,520 mg] daily).
Iron deficiency anemia (nondialysis CKD): Oral: One tablet (ferric iron 210 mg) 3 times daily; titrate dose as needed to achieve and maintain target hemoglobin level (maximum dose: 12 tablets [ferric iron 2,520 mg] daily). Note: In one clinical trial, dose titration occurred at 4-week intervals to achieve desired hemoglobin levels; dose was increased only if serum phosphorus level ≥3 mg/dL, was decreased if serum phosphorus level <2.5 mg/dL, and temporarily discontinued if serum phosphorus level <2 mg/dL (Fishbane 2017).
Refer to adult dosing.
Dosing: Renal Impairment
No dosage adjustment necessary.
Dosing: Hepatic Impairment
There are no dosage adjustments provided in the manufacturer's labeling.
Administer with meals. Do not chew or crush tablets (may discolor mouth and teeth).
Ensure adherence with prescribed diet.
Store at 20°C to 25°C (68°F to 77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F). Protect from moisture.
Alpha-Lipoic Acid: Iron Salts may decrease the absorption of Alpha-Lipoic Acid. Alpha-Lipoic Acid may decrease the absorption of Iron Salts. Consider therapy modification
Baloxavir Marboxil: Iron Salts may decrease the serum concentration of Baloxavir Marboxil. Avoid combination
Bictegravir: Iron Salts may decrease the serum concentration of Bictegravir. Management: Bictegravir, emtricitabine, and tenofovir alafenamide can be administered with iron salts under fed conditions, but coadministration with or 2 hours after an iron salt is not recommended under fasting conditions. Consider therapy modification
Bisphosphonate Derivatives: Iron Salts may decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of oral iron supplements within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate. Exceptions: Pamidronate; Zoledronic Acid. Consider therapy modification
Cefdinir: Iron Salts may decrease the serum concentration of Cefdinir. Red-appearing, non-bloody stools may also develop due to the formation of an insoluble iron-cefdinir complex. Management: Avoid concurrent cefdinir and oral iron when possible. Separating doses by several hours may minimize interaction. Iron-containing infant formulas do not appear to interact with cefdinir. Consider therapy modification
Deferiprone: Iron Salts may decrease the serum concentration of Deferiprone. Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours. Consider therapy modification
Dimercaprol: May enhance the nephrotoxic effect of Iron Salts. Avoid combination
Dolutegravir: Iron Salts may decrease the serum concentration of Dolutegravir. Management: Administer dolutegravir at least 2 hours before or 6 hours after oral iron. Administer dolutegravir/rilpivirine at least 4 hours before or 6 hours after oral iron salts. Alternatively, dolutegravir and oral iron can be taken together with food. Consider therapy modification
Eltrombopag: Iron Salts may decrease the serum concentration of Eltrombopag. Management: Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any iron-containing product. Consider therapy modification
Entacapone: Iron Salts may decrease the serum concentration of Entacapone. Management: Consider separating doses of the agents by 2 or more hours to minimize the effects of this interaction. Monitor for decreased therapeutic effects of levodopa during concomitant therapy, particularly if doses cannot be separated. Consider therapy modification
Levodopa: Iron Salts may decrease the serum concentration of Levodopa. Only applies to oral iron preparations. Management: Consider separating doses of the agents by 2 or more hours to minimize the effects of this interaction. Monitor for decreased therapeutic effects of levodopa during concomitant therapy, particularly if doses cannot be separated. Consider therapy modification
Levothyroxine: Iron Salts may decrease the serum concentration of Levothyroxine. Management: Separate oral administration of iron salts and levothyroxine by at least 4 hours. Separation of doses is not required with parenterally administered iron salts or levothyroxine. Consider therapy modification
Methyldopa: Iron Salts may decrease the serum concentration of Methyldopa. Consider therapy modification
PenicillAMINE: Iron Salts may decrease the absorption of PenicillAMINE. Only oral iron salts are a concern. Management: Separate the administration of penicillamine and oral iron salts by at least 1 hour. Consider therapy modification
Phosphate Supplements: Iron Salts may decrease the absorption of Phosphate Supplements. Management: Administer oral phosphate supplements as far apart from the administration of an oral iron salt as possible to minimize the significance of this interaction. Exceptions: Sodium Glycerophosphate Pentahydrate. Consider therapy modification
Quinolones: Iron Salts may decrease the serum concentration of Quinolones. Management: Give oral quinolones at least several hours before (4 h for moxi- and sparfloxacin, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome-, 3 h for gemi-, and 2 h for levo-, nor-, oflox-, pefloxacin, or nalidixic acid) oral iron salts Exceptions: LevoFLOXacin (Oral Inhalation). Consider therapy modification
Tetracyclines: May decrease the absorption of Iron Salts. Iron Salts may decrease the serum concentration of Tetracyclines. Exceptions: Eravacycline. Consider therapy modification
Trientine: May decrease the serum concentration of Iron Salts. Iron Salts may decrease the serum concentration of Trientine. Management: Trientine manufacturer recommends avoiding concurrent use with oral iron salts due to the risk for impaired GI absorption of both trientine and the iron salt. Short courses of iron may be used; however, separate administration by at least 2 hours. Consider therapy modification
>10%: Gastrointestinal: Darkening of stools (19% to 22%), diarrhea (21%), constipation (8% to 18%), nausea (10% to 11%)
1% to 10%:
Endocrine & metabolic: Hyperkalemia (5%)
Gastrointestinal: Vomiting (7%), abdominal pain (5%)
Respiratory: Cough (6%)
Concerns related to adverse effects:
• Iron toxicity: May increase serum iron, ferritin, and transferrin saturation (TSAT), which may lead to excessive elevations in iron stores. Evaluate serum iron, ferritin, and TSAT at baseline and during therapy.
• Stool discoloration: May cause discolored (dark) stools related to iron content.
Concurrent drug therapy issues:
• Iron supplements: Patients receiving parenteral iron supplementation may require a dose reduction or discontinuation when ferric citrate is initiated.
• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.
• Overdose: Contains iron, a leading cause of fatal poisoning in children <6 years of age. Keep out of reach of children; in case of accidental overdose, immediately contact a poison control center or a health care provider.
Serum iron, ferritin, and transferrin saturation (TSAT) at baseline and during therapy; serum phosphorus (periodically)
Animal reproduction studies have not been conducted. Use of ferric citrate may increase iron stores, which may cause adverse events in pregnancy (fetal malformations, spontaneous abortion, and gestational diabetes noted with iron overdose in pregnant women).
• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
• Patient may experience cough or dark stools. Have patient report immediately to prescriber severe nausea, severe vomiting, severe diarrhea, or severe constipation (HCAHPS).
• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about ferric citrate
- Ferric citrate Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- En Español
- 2 Reviews
- Drug class: phosphate binders
Other brands: Auryxia